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Reliable predictions on the risk and survival time of prostate cancer patients based on
their clinical records can help guide their treatment and provide hints about the disease
mechanism. The Cox regression is currently a commonly accepted approach for such tasks
in clinical applications. More complex methods, like ensemble approaches, have the potential
of reaching better prediction accuracy at the cost of increased training difficulty and worse
result interpretability. Better performance on a specific data set may also be obtained by
extensive manual exploration in the data space, but such developed models are subject to
overfitting and usually not directly applicable to a different data set. We propose DWCox,
a density-weighted Cox model that has improved robustness against outliers and thus can
provide more accurate predictions of prostate cancer survival. DWCox assigns weights to the
training data according to their local kernel density in the feature space, and incorporates
those weights into the partial likelihood function. A linear regression is then used to predict
the actual survival times from the predicted risks. In the 2015 Prostate Cancer DREAM
Challenge, DWCox obtained the best average ranking in prediction accuracy on the risk and
survival time. The success of DWCox is remarkable given that it is one of the smallest and
most interpretable models submitted to the challenge. In simulations, DWCox performed
consistently better than a standard Cox model when the training data contained many
sparsely distributed outliers. Although developed for prostate cancer patients, DWCox can
be easily re-trained and applied to other survival analysis problems. DWCox is implemented
in R and can be downloaded from https://github.com/JinfengXiao/DWCox.
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CHAPTER 1: INTRODUCTION
Prostate cancer is the 2nd leading cause of cancer death in men in the United States [1]
and the 6th worldwide [2]. In the past 10 years more than 2 million men in the US suf-
fered from prostate cancer, and about 5% of those patients had metastatic castrate-resistant
prostate cancer (mCRPC), an advanced form of the disease whose outcomes are poor and
treatment remains unclear. Survival analysis based on clinical records has attracted re-
searchers’ attention, since it can hopefully direct cancer treatment and help elucidate the
disease mechanism.
The Cox regression [3], also known as the proportional hazards model, is a classic model
in survival analysis. The simplicity and interpretability of the Cox model come from the
proportional hazards assumption, which basically states that the risk can be estimated based
on a linear combination of the predictive variables. A trained Cox model can calculate a
relative risk score for a new patient based on his/her clinical information, and is thus able
to rank patients with their expected order of death. It cannot, though, directly predict the
expected time to death.
The Cox-based model proposed by Halabi et al. in 2014 [4] (referred to as Halabi’s model
in the rest of this manuscript) is a state-of-the-art method for clinical prediction of prostate
cancer survival. Halabi’s model is outlined in Figure 1.1(a). It starts with 22 features
(“Halabi’s 22 features”), including some previously defined predictors of overall survival and
some clinical parameters, picks out the eight most important features (“Halabi’s 8 features”)
using L1 regularization, and predicts patients’ risks using those eight features only.
We propose DWCox, a density-weighted Cox model for predicting prostate cancer
survival. DWCox was a best-performing method in the 2015 Prostate Cancer DREAM
Challenge (PCDC), with performance better than or comparable to the best ensemble
approaches. Simulations have shown that DWCox can achieve better performance than a
standard Cox model when many sparsely distributed outliers exist in training data. DW-
Cox is implemented in R in a way such that it can be easily re-trained and applied to other
survival analysis problems, not restricted to prostate cancer. Please refer to the section
“Data and software availability” for a download link and a citable link to the software.
The remaining of this thesis is organized as follows. In Chapter 2, I will introduce the
methodology of DWCox and its novelty. In Chapter 3, I will outline the experiments, real
or simulated, used to develop and validate DWCox. Chapter 4 presents the main results
about the performance of DWCox on real and simulated data. Chapter 5 discusses the main
achievements, limitations, and extensibility of DWCox. Chapter 6 gives instructions on how
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to access the data and codes relevant to this thesis.
Figure 1.1: Illustration of how Halabi’s model (a) and DWCox (b) predict the risk scores.
DWCox is also able to predict the days to death using linear regression with the risk scores
(not demonstrated in this figure). N : number of patients. MICE: Multivariate Imputation
by Chained Equations. L1: Lasso regularization. DW: Density-based weighting. Note that




DWCox assigns weights to the training data according to their local kernel density in the
feature space, and then trains an adopted Cox model with those weights incorporated into
the loss function, as demonstrated in Figure 1.1(b). DWCox can also predict the actual
survival time from the predicted risk score using a linear regression.
The development of DWCox underwent two phases. It was first developed and tested
during the PCDC, and then further refined after its success. In this paper, unless something
is stated to happen during the PCDC, DWCox should be understood as what it is now after
the post-challenge refinements.
2.1 FEATURE CONSTRUCTION
Training DWCox requires a training group of N patients whose clinical features X and
survival outcomes Y are known. X is an N -by-M matrix, where M is the number of clinical
features and each element Xij is the value of the jth clinical feature of the ith patient. Y is
an N -by-2 matrix, where each row gives the survival outcome of a patient. The 1st column
of Y is a vector of the last observed survival time t, and the 2nd column is a vector of binary
event indicators d. A patient i with di= TRUE is known to die at time ti. Oppositely, one
with di= FALSE is known to be alive at time ti, but no information is available after ti.
In the latter case, the record of that patient is said to be censored. In the data sets used in
the PCDC, Y is known, while X needs to be constructed from clinical data.
2.1.1 20 Features
To ensure fair comparison with Halabi’s model, DWCox constructed X in line with the
way Halabi defined his 22 features, as summarized in Table 2.1 and described in details as
below. Note that two features Halabi’s model started with, namely the Charlson comorbid-
ity index and the Biopsy Gleason score, were not considered by DWCox since during the
PCDC the former was not available in the training data and the latter was 100% missing in
the leaderboard data. (Data were split into training, leaderboard and final validation sets.
Details will be described in the Experiments section). That means M = 20.
The following are details about the 20 predictors used by DWCox in the PCDC.
• age: Categorical variable with 3 levels. 18-64 years old = 1; 65-74 years old = 2; at
least 75 years old = 3.
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• alb: Albumin level in g/L. Continuous variable.
• alp: Natural logarithm of the alkaline phosphatase level in U/L. Continuous variable.
• alt: Natural logarithm of the alanine transaminase level in U/L. Continuous variable.
• analgesics: Prior analgesics use. Binary variable. 1 means yes; 0 means no. Note that
this is not exactly the ”opioid analgesic use” as appeared in the baseline paper, since
the latter is not contained in the challenge data set.
• ast: Natural logarithm of the aspartate aminotransferase level in U/L. Continuous
variable.
• bili: Natural logarithm of the total bilirubin level in µmol/L. Continuous variable.
• bmi: Natural logarithm of the body mass index in kg/m2. Continuous variable.
• ds: Disease site. Categorical variable with 3 levels. 0 means the disease sites are not
at bones or viscera. 1 means the disease sites are at bones but not at viscera. 2 means
at least some disease sites are at viscera.
• ecogps: Eastern Cooperative Oncology Group performance status. Categorical variable
with 3 levels (0, 1 and 2). The greater the value is, the more severe the situation is
for the patient. Technically this variable should have 6 levels (0, 1, ..., 5), but Halabi’s
model only considers the first 3 levels. Besides, in the challenge training data there is
only 1 patient whose ecogps is greater than 2 (and it is 3). Therefore DWCox sets all
ecogps > 2 to 2.
• hb: Hemoglobin level in g/dL. Continuous variable.
• ldh: Lactate dehydrogenase level. Binary variable. 1 means the lactate dehydrogenase
level is greater than 200 units/liter, which is considered as the value of the upper limit
of normal (ULN) [5]. 0 means the opposite.
• liver: Liver metastases. Binary variable. Yes = 1; No = 0.
• lung: Lung metastases. Binary variable. Yes = 1; No = 0.
• plt: Natural logarithm of the platelet count in 109/L. Continuous variable.
• psa: Natural logarithm of the prostate-specific antigen level in ng/mL. Continuous
variable. The reason for taking logarithm is to make the distribution less skewed.
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• race: categorical variable with 4 levels. White = 1; Asian = 2; Black = 3; Other or
Hispanic = 4.
• radio: Prior radiotherapy. Binary variable. Yes = 1; No = 0.
• testo: Testosterone level in nmol/L. Continuous variable.
• wbc: Natural logarithm of the white blood cell count in 109/L. Continuous variable.
2.1.2 Imputation
At this stage X was not complete (i.e. there were many missing elements in that matrix)
due to missing information in the raw clinical records. Those missing values in X were
imputed with the algorithm Multivariate Imputation by Chained Equations (MICE) [6, 7].
The idea of MICE is to use Bayesian statistics to iteratively infer the missing values from
other known and previously inferred values. Missing values in the training data were imputed
with knowledge about the survival outcome, since it was argued that the outcomes could
help generate less biased imputations [8]. The survival outcome was incorporated into the
imputation in the form of the NelsonAalen estimator as suggested by White and Royston [9].
Imputation on the leaderboard and final validation data were done without using the survival
outcome.
2.1.3 Historical Notes
During the PCDC, three more binary features were used to indicate the trial ID (described
in the Experiments section) of each patient. Those features were removed in post-challenge
analysis so that the performance of DWCox does not depend on prior knowledge about the
data source.
2.2 DENSITY-BASED WEIGHTING
After the imputation, the N -by-M matrix X can be represented by N points scattered in
a M -dimensional space F (“feature space”). Each point represents a patient whose each
coordinate is the value of one of his/her M clinical features. We assign each patient i a
weight wi ∈ [0, 1] proportional to the estimated local Gaussian kernel density in the feature
space. To calculate wi, we used the default settings of the function kepdf in the R package
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pdfCluster [10]. These weights were then divided by the maximum value. Thus a patient
with a higher weight indicates there are more other patients with similar clinical features.
2.3 MODEL TRAINING



















where β is a vector of the regression coefficients, Xj denotes the jth row of X, t1 < t2 <
· · · < ti < · · · < tm is an increasing list of death times in Y, and Di is the set of patients
died at time ti.
During the PCDC, L2 regularization was imposed to the objective function. The penalty
weight was chosen to optimize the model performance (more specifically, iAUC, as defined
in the next subsection) averaged over 100 repeated random sub-sampling validation on the
training data. In each random sub-sampling validation experiment, 2/3 of all the training
data were randomly selected to train the model with a wide range of possible penalty weights,
and the iAUC was evaluated for each possible penalty weight on the remaining 1/3 of the
training data. After the PCDC, the regularization was removed from DWCox since its
contribution to the model performance was not obvious during the challenge and its removal
sped up training.
After model training, the risk vector r of the training patients were calculated as
r = Xβ̂. (2.2)
A higher risk indicates a shorter expected remaining lifetime for a patient. A linear regression
t = k̂r + b̂ + e was then performed to correlate t to r, where k̂ and b̂ were the regression
coefficients, and e was the error between the actual survival time and the estimated value
(i.e. t = t̂ + e, where t̂ = k̂r + b̂).
2.4 PREDICTION AND EVALUATION
The trained model was used to predict the risk rtest and the remaining lifetime ttest for a
new group of patients whose clinical features Xtest could be constructed from clinical data
while the outcome Ytest was not seen by the model. The model performance was then
evaluated by comparing rtest and ttest to Ytest.
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The predicted risks rtest were evaluated with the integrated area under the ROC curve
(iAUC) as described below. After obtaining β̂ by maximizing Eq. (2.1), we can estimate the
risks of the patients rtest = Xtestβ̂. Then an estimated order of death ô can be constructed
by sorting rtest (i.e. ôi = j where i = 1, 2, . . . , N and rtest,i is the jth smallest element of
rtest). By comparing ô with the actual outcome Ytest, at any given time threshold ti we can
calculate the area under the receiver operating characteristic curve AUCti . If we integrate
AUCti with respect to ti from the 6th to the 30th month, we get the integrated area under
curve iAUC ∈ [0, 1]. The greater the iAUC, the better the predicted risks reflect the actual
order of death.
DWCox also gives the estimated time to death of the test set: t̂test = k̂rtest + b̂. In the
PCDC t̂test was evaluated by its RMSE from ttest.
2.5 EXTENSIBILITY
The open-source release of DWCox is coded in a way such that it can be easily re-trained
and applied to other survival analysis problems, not restricted to prostate cancer. To re-train
and apply DWCox to a new dataset, users simply need to:
• Format their data into the three matrices X, Y and Xtest.
• Hit enter and get some coffee.
• Now they get the predicted risk rtest and time to event t̂test.
Here X and Xtest can have as many rows (i.e. subjects) and columns (i.e. features) as needed.











































































































































































































































































































































































































































3.1 CHALLENGE DATA AND CONTEXT
DWCox has been developed and evaluated with data from the comparator arms of four
phase III clinical trials with over 2,000 mCRPC patients in total treated with first-line
docetaxel. Those four trials and the corresponding data providers are:
• ASCENT-2 (Novacea, provided by Memorial Sloan Kettering Cancer Center) [12],
• MAINSAIL (Celgene) [13],
• VENICE (Sanofi) [14], and
• ENTHUSE-33 (AstraZeneca) [15].
During the PCDC those trials were referred to with their study IDs (Table 3.1).
Table 3.1: Clinical trials used to develop DWCox.
Trial Study ID Number of Patients Survival Outcome
ASCENT-2 ASCENT2 476 Known
MAINSAIL CELGENE 526 Known
VENICE EFC6546 598 Known
ENTHUSE-33 AZ 470 Hidden
The development and evaluation of DWCox began with the 2015 Prostate Cancer DREAM
Challenge and continued after the challenge. The full anonymized information about the
patients in trials ASCENT-2, MAINSAIL and VENICE was released to the challenge partic-
ipants. As for trial ENTHUSE-33, the participants only knew the clinical records available
at the beginning of the trial (”baseline clinical records”), while data obtained after the start
of the trial including the survival outcome were visible only to the challenge organizers.
The challenge goal was to develop models that used the baseline clinical records to predict
the patients’ relative risk (sub-challenge 1a), days till death (sub-challenge 1b), and
treatment discontinuation (sub-challenge 2) (Table 3.2).
DWCox was trained on Trials ASCENT-2, MAINSAIL and VENICE (“PCDC training
data”) by the authors, and evaluated on Trial ENTHUSE-33 (“PCDC validation data”)
by the challenge organizers. Trial ENTHUSE-33 was further divided into a leaderboard set
9
Table 3.2: Three sub-challenges of the PCDC.
Sub-Challenge What to Predict Evaluation Metric Our Participation
1a Relative risk iAUC Yes
1b Days to death RMSE Yes
2 Treatment discontinuation (Irrelevant) No
(157 patients) and a validation set (313 patients). The leaderboard set was used to run
three leaderboard rounds. In each round, the challenge organizers randomly subsampled
80% patients from the leaderboard set, evaluated the participants’ models on that random
sample, and returned the feedback to the participants. After the 3rd leaderboard round,
each participating team submitted a final model, whose performance on the validation set
was used to rank the teams. Bootstrapping was performed by the challenge organizers to
make sure the winning teams gave statistically significantly better predictions than other
teams and Halabi’s model. DWCox was involved in the leaderboard rounds of sub-challenge
1a and the final scoring round of sub-challenges 1a & 1b.
3.2 SIMULATIONS
Simulation experiments were performed to evaluate the contribution of density-based
weighting to the model performance. DWCox was trained and evaluated on 100 simulated
data sets (one example is given in Figure 3.1) separately, each of which was designed to
mimic the real challenge data to some extent, while the randomness in the data generation
process assured the variation across simulations. In each simulation, three groups of patients
were simulated. Each patient had 20 features and an outcome.
One group (“signal group”) represented a group of 1,000 patients that reflected the true
correlation between the outcome and the features. The features were sampled from Gaussian
distributions:
Xsignal,ij ∼ N (µj, σ2j ) (3.1)
where µj and σj were the mean and standard deviation of the jth feature in the PCDC train-
ing data. Following the idea of R. Bender et al. [16], we simulated the survival time of each










Figure 3.1: (Best viewed in color.) Scatter plot of the first two principle components of the
signal, noise and validation groups in a simulated data set. Each point represents a patient.
The shapes mark the mean of each group.
where usignal,i ∼ U(0, 1), λ > 0, ν > 0, and the subscript i∗ takes the ith row of the matrix.
U( , ) denotes uniform distributions.
We would like to clarify a few things about Eq. (3.2). Readers may get confused if they
see an online manuscript with the same title and authors as those of Reference [16], where
the minus sign of Eq. (3.2) is outside the parenthesis. Obviously it is a typo, and it has been
corrected in the version cited here. Although Eq. (3.2) may not look like a Weibull distribu-
tion at first glance, the proof is a very straightforward and standard procedure. The shape







Such generated survival times follow a Cox model with the baseline hazard function h0(t) =
λνtν−1 [16]. The parameters λ, ν and β were estimated from the un-censored part of the
PCDC training data as follows. First, we assumed β = 0 and fit a Weibull distribution
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to the distribution of tuncensored to estimate ν and λ. Then DWCox was applied to the
PCDC training data to obtain β̂. At this stage β̂ did not include β̂0, a constant term that
affected t̂ but not iAUC, since β̂0 played no role during the maximization process of Eq.
(2.1). We chose a β̂0 value such that the mean of the survival times simulated with Eq. (3.2)
was close to the mean of the uncensored survival times in the PCDC training data. After
getting the estimates of λ, ν and β, tsignal was simulated with Eq. (3.2).
We then generated 1,000 more patients (“noise group”) to represent outliers, or noises,
in the training data. We made the outliers more sparsely and widely distributed in the
feature space than the signal group by simulating
Xnoise,ij ∼ N (c1jµj, (c2jσj)2) (3.3)
where c1j ∼ U(0.5, 1.5) and c2j ∼ U(2, 4). In this section, identical mathematical symbols
present in multiple equations (e.g. µj in Eq. (3.1)(3.3)) share the same definitions and
values.








where unoise,i ∼ U(0, 1).
A 3rd group of 500 patients (“validation group”) was generated in a fashion similar to
that of the signal group. We let
Xvali,ij ∼ N (c3jµj, (c4jσj)2) (3.5)









where uvali,i ∼ U(0, 1).
After simulating the three groups of patients, we mixed the signal and noise groups to-
gether to form a training set. DWCox and a 20-feature standard Cox model were trained
on this training set, and evaluated with iAUC on the validation group.
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CHAPTER 4: RESULTS
DWCox was submitted to the sub-challenges 1a & 1b (Table 3.2) of the 2015 Prostate
Cancer DREAM Challenge. Sub-challenge 1a aimed at better predictions on the relative
risks and order of death, evaluated with iAUC. Sub-challenge 1b evaluated the models using
the RMSE between the predicted days to death and the actual time. While this manuscript
is focused on our method, more details about other teams’ methods and performance can
be found in papers from the challenge organizers and individual teams.
4.1 HETEROGENEITY IN THE PCDC DATA
Analysis of the PCDC data suggests that there exists rather high heterogeneity across
the three training trials and the validation trial. The missing-rate profile of the 20 clinical
features varies across trials (Figure 4.1). The average values of the first two principle com-
ponents of the 20 features of Trial ASCENT-2 is farther away from those of the validation
trial, compared to those of the other two training trials (Figure 4.2). Leave-one-trial-out
cross-validation (i.e. to train with two training trials and evaluate with the left-out training
trial) gives very different results when different trials are left out (Table 4.1).





Those facts give such a clue: If we consider the “true model” underlying the validation
trial as the signal, it is very likely that the PCDC training data contain many outliers.
Those outliers do not follow the “true model”, and thus tend to bring down the validation-
set performance of models that failed to deal with the outliers properly during training.
Therefore robustness against outliers is probably important to models aimed at winning the
PCDC.
Indeed, several other winning teams of the PCDC tried hard to deal with the outliers
in the training data. For example, the top performer (FIMM-UTU) of sub-challenge 1a
decided to discard the entire ASCENT-2 trial, because after some manual exploration in
the data space they found significant differences in clinical variables that set this trial apart
13
Figure 4.1: Heatmap of the percentage missing of the 20 clinical features used in DWCox.
 
 
































from the other trials. Our team (Team Cornfield) instead used all available data and let
DWCox automatically handle the outliers.
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Figure 4.2: (Best viewed in color.) Scatter plot of the first two principle components of the
four prostate cancer trials. Each point represents a patient. The shapes mark the average
values of each trial.
4.2 RESULTS ON THE PCDC DATA
DWCox obtained the best average ranking in sub-challenges 1a & 1b among about 50
models (Figure 4.3). On the PCDC validation data, DWCox gave an iAUC of 0.7789 and
a RMSE of 194.8650 days, out-performing Halabi’s model which gave an iAUC of 0.7581
and a RMSE of 196.6704 days. Bootstrapping has shown that DWCox outperforms Halabi’s
model with a Bayes Factor (BF) > 3. Note that while the other numbers in this paragraph
are official results provided by the challenge organizers, the Halabi RMSE is not. In order
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to get the Halabi RMSE, we implemented a Halabi’s model and appended to it a linear
regression step similar to the one in DWCox. After applying bootstrapping and the BF > 3
threshold against other teams’ submissions, the challenge organizers reported DWCox as a
winner in sub-challenge 1b and a runner-up in sub-challenge 1a. The winner sub-challenge
1a, FIMM-UTU, obtained an iAUC of 0.7915 and a RMSE of 201.3779 days. Their model
is an ensemble of penalized cox regressions developed with extensive manual exploration
in the data space. More details about the challenge results can be found at https://www.
synapse.org/#!Synapse:syn2813558/wiki/232674. Table 2.1 gives the regression coefficients
determined by DWCox.
Figure 4.3: Ranking of the top teams in sub-challenges 1a & 1b. The six best teams of each
sub-challenge are included. DWCox was submitted by the authors’ Team Cornfield.
An inverse correlation between the actual survival time t and risk scores r was observed
(Figure 4.4). Note that the adjusted R2 of the linear regression t̂ = k̂r+ b̂ is small (0.1513),
and the shape of the t vs r plot implies that there may exist models better than a linear
regression for capturing their correlation.
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Figure 4.4: Scatter plot of the uncensored survival time versus the predicted risk on the
PCDC training data. The straight line is the linear regression line with slope = -234.6,
intercept = 810.3 and adjusted R2 = 0.1513.
4.3 FULL FEATURE SPACE OF THE PCDC
We would like to note that DWCox achieved its superior performance by only using a very
small subset of all available features. Among more than 150 independent and standardized
variables over the trials [17], DWCox only involves 20. This achievement is remarkable,
since there were other teams in the challenge that utilized as many features as possible
without reaching prediction accuracy as high as DWCox did. That indicates that most of
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the available features in the full available feature space share some redundancy with the
features utilized by DWCox. We hereby provide a list of all available features in Chapter 7
for readers’ reference.
In the PCDC, the clinical variables were organized into six tables: A core table with
patients demographic information, as well as five standardized raw event-level tables: labo-
ratory values, medical history, lesion sites, previous treatments, and vital signs.
4.4 RESULTS ON SIMULATED DATA
In the 100 repeated simulations (described in the Experiments section), DWCox performed
better than a standard Cox model when as many as half of the training data were outliers.
DWCox not only gave better average performance over the 100 experiments (Table 4.2,
Figure 4.5), but also performed consistently better in each experiment (Figure 4.6, paired
t-test p-value = 2.1 × 10−20). The improvement in performance clearly resulted from the
density-based weighting, since everything else was the same across the two models.




Note that in the simulations we used iAUC but not the RMSE to evaluate model per-
formance. There are three reasons for that. 1) iAUC evaluates model performance on
the validation data in a more comprehensive manner, while RMSE is based on individual
predictions which are independent of each other. 2) DWCox’s time-to-event prediction is de-
pendent on its predicted risks. 3) A standard Cox model does not directly give the predicted
time-to-event.
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Figure 4.5: Boxplot of the iAUC of DWCox and a standard Cox model in 100 simulations.
The boxes show the medians and inter-quartile ranges (IQR). The vertical black lines extends
from the boxes by at most 1.5 IQR. Black points represent experiments whose iAUC is more
than 1.5 IQR away from the boxes.
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Figure 4.6: DWCox iAUC vs the standard Cox iAUC in 100 simulations. Each point is given
by a simulation. The straight line has slope = 1 and intercept = 0.
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CHAPTER 5: DISCUSSION
We propose DWCox, a density-weighted Cox model for survival analysis that is more
robust against overfitting outliers from the training data. In our simulations DWCox out-
performed the standard Cox when as many as half of the training data were noise. In the
2015 Prostate Cancer DREAM Challenge (the PCDC), DWCox obtained the best average
ranking in sub-challenge 1, which was to predict the risk and survival time of prostate cancer
patients from clinical data available at the beginning of trials.
DWCox was one of the only two models among the seven winners of the PCDC sub-
challenge 1 that did not use super-learners (or ensemble methods). (The other model [18]
of the two was a standard Cox trained with different features. In Figure 4.3 the corre-
sponding team name is M S.) This is a remarkable achievement, since super-learners usually
give better results than single methods. Given that now DWCox gives results comparable
to or better than ensemble methods, there are even more reasons to prefer DWCox over
ensemble ones in real-world applications. During the training of ensemble methods, there
often exist some empirical parameters (e.g. the number of base learners to use) that require
more hyperparameter tuning, because people do not know exactly which value works best
and why. In addition, some ensemble methods (e.g. random forests) have great built-in
randomness and produce very complex models, and thus it is sometimes hard to interpret
and understand the results they give. Oppositely, the training phase of DWCox involves no
empirical parameters or built-in randomness (except when the user wants DWCox to impute
the missing data with MICE), and the results can be easily interpreted.
DWCox’s success in the PCDC should be credited to its density-based weighting mecha-
nism. There exists inter-trial heterogeneity in the PCDC data, which implies some training
trials may contribute more signals than others, while some may contain more outliers. It
turned out that several top-performing methods of the PCDC recognized such problem and
tried to handle it properly. DWCox achieved this by taking in all training data and auto-
matically weighting away outliers with the local Gaussian kernel density. DWCox can be
easily re-trained and applied to other data sets, not restricted to prostate cancer survival
data.
Perhaps the greatest limitation of DWCox also lies in its density-based weighting mech-
anism. Such mechanism cannot weight away outliers falling inside the signaling region of
the feature space, or outliers that happen to cluster together in the feature space and thus
give a local kernel density similar to those of the signals. In another extreme case where the
data contain few outliers and follow a standard Cox model rather well, introducing weights
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into the partial likelihood function can make the performance worse. Therefore it is better
to apply DWCox to cases where the data are expected to contain some sparsely distributed
outliers.
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CHAPTER 6: DATA AND SOFTWARE AVAILABILITY
This publication is based on research using information obtained from www.projectdatasphere.
org, which is maintained by Project Data Sphere, LLC. Neither Project Data Sphere, LLC
nor the owner(s) of any information from the web site have contributed to, approved or are
in any way responsible for the contents of this publication.
The clinical trial data used in the PCDC, in its raw and processed format, can be ac-
cessed at: https://www.projectdatasphere.org/projectdatasphere/html/content/149?pcdc=
true. Challenge documentation, including the detailed description of the Challenge de-
sign, overall results, scoring scripts, and the clinical trials data dictionary can be found at:
https://www.synapse.org/ProstateCancerChallenge.
An R implementation of DWCox can be downloaded from https://github.com/JinfengXiao/
DWCox. A citable snapshot of that GitHub repository has also been archived with this DOI:
10.5281/zenodo.167143.
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CHAPTER 7: SUPPLEMENTARY TABLES
This chapter gives the supplementary tables referred to by the previous chapters. Those
tables describe the full feature space about the prostate cancer patients, accessible to models
in the the PCDC. Some redundant or very sparse features are not included.
Table 7.1: Demographic and core medical features.
Feature Name Description
PER REF Reference Day used for ENTRT PC
LKADT REF Reference Day used for LKADT P
LKADT PER Period unit for period values, LKADT P
AGEGRP Age Group
AGEGRP2 Age Group (3 Category)
RACE C Race
BMI Baseline Body Mass Index (kg/m2)
HEIGHTBL Baseline Height In cm
HGTBLCAT Baseline Height In cm Category
WEIGHTBL Baseline Weight In kg
WGTBLCAT Baseline Weight In kg Category
REGION C Region Of The World
ECOG C Baseline Patient Performance Status
ALP Baseline Lab Value: Alkaline Phosphatase U/L
ALT Baseline Lab Value: Alanine Transaminase U/L
AST Baseline Lab Value: Aspartate Aminotransferase U/L
CA Baseline Lab Value: Calcium mmol/L
CREAT Baseline Lab Value: Creatinine umol/L
HB Baseline Lab Value: Hemoglobin g/dL
LDH Baseline Lab Value: Lactate Dehydrogenase U/L
NEU Baseline Lab Value: Neutrophils 109/L
PLT Baseline Lab Value: Platelet Count 109/L
PSA Baseline Lab Value: Prostate Specific Antigen ng/mL
TBILI Baseline Lab Value: Total Bilirubin umol/L
TESTO Baseline Lab Value: Testosterone nmol/L
WBC Baseline Lab Value: White Blood Cells 109/L
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Table 7.1 Continued.
CREACL Baseline Lab Value: Creatinine Clearance ml/Min
NA Baseline Lab Value: Sodium mmol/L
MG Baseline Lab Value: Magnesium mmol/L
PHOS Baseline Lab Value: Phosphorus mmol/L
ALB Baseline Lab Value: Albumin g/L
TPRO Baseline Lab Value: Total Protein g/L
RBC Baseline Lab Value: Red Blood Cells 1012/L
LYM Baseline Lab Value: Lymphocytes 109/L
BUN Baseline Lab Value: Blood Urea Nitrogen mmol/L
CCRC Baseline Lab Value: Calculated Creatinine Clearance mL/min
GLU Baseline Lab Value: Glucose mmol/L
CREACLCA Baseline Lab Value: Creatinine Clearance Calcul. (Cockcroft
And Gault) ml/min
NON TARGET Baseline Non-Target Lesion(s), Target Vs. Non-Target Lesion
Definition See Wiki Data Description
TARGET Baseline Target Lesion(s), Target Vs. Non-Target Lesion Defini-
tion See Wiki Data Description
BONE Baseline Bone Lesion(s)
RECTAL Baseline Rectal Lesion(s)
LYMPH NODES Baseline Lymph Node Lesion(s)
KIDNEYS Baseline Kidney Lesion(s)
LUNGS Baseline Lung Lesion(s)
LIVER Baseline Liver Lesion(s)
PLEURA Baseline Pleura Lesion(s)
OTHER Baseline Other Lesion(s)
PROSTATE Baseline Prostate Lesion(s)
ADRENAL Baseline Adrenal Lesion(s)
BLADDER Baseline Bladder Lesion(s)
PERITONEUM Baseline Peritoneum Lesion(s)
COLON Baseline Colon Lesion(s)
HEAD AND NECK Baseline Head And Neck Lesion(s)
SOFT TISSUE Baseline Soft Tissue Lesion(s)
STOMACH Baseline Stomach Lesion(s)
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Table 7.1 Continued.
PANCREAS Baseline Pancreas Lesion(s)
THYROID Baseline Thyroid Lesion(s)
ABDOMINAL Baseline Abdominal Lesion(s)




















ACE INHIBITORS Prior Ace Inhibitors
BETA BLOCKING Prior Beta Blocking Agents
HMG COA REDUCT Prior HMG COA Reductase Inhibitors
ESTROGENS Prior Estrogens
ANTI ESTROGENS Prior Anti-Estrogens
ARTTHROM Medical History: Arterial Thrombosis
CEREBACC Medical History: Cerebrovascular Accident (Hemorrhagic
And/Or Ischemic)
CHF Medical History: Congestive Heart Failure
DVT Medical History: Deep Venous Thrombosis (DVT)
DIAB Medical History: Diabetes
GASTREFL Medical History: Gastroesophageal Reflux Disease (GERD)
GIBLEED Medical History: Gastrointestinal (GI) Bleed
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Table 7.1 Continued.
MI Medical History: Myocardial Infarction (MI)
PUD Medical History: Peptic Ulcer Disease (PUD)
PULMEMB Medical History: Pulmonary Embolism (PE)
PATHFRAC Medical History: Pathological Bone Fractures
SPINCOMP Medical History: Spinal Cord Compression
COPD Medical History: Chronic Obstructive Pulmonary Disease
MHBLOOD Medical History (Body System): Blood & Lymphatic System
MHCARD Medical History (Body System): Cardiac Disorders
MHCONGEN Medical History (Body System): Congenital, Familial & Genetic
MHEAR Medical History (Body System): Ear & Labyrinth
MHENDO Medical History (Body System): Endocrine Disorders
MHEYE Medical History (Body System): Eye Disorders
MHGASTRO Medical History (Body System): Gastrointestinal Disorders
MHGEN Medical History (Body System): Gen Disord & Admin Site
MHHEPATO Medical History (Body System): Hepatobiliary Disorders
MHIMMUNE Medical History (Body System): Immune System Disorders
MHINFECT Medical History (Body System): Infections & Infestations
MHINJURY Medical History (Body System): Injury, Poison & Procedural
MHINVEST Medical History (Body System): Investigations
MHMETAB Medical History (Body System): Metabolism & Nutrition
MHMUSCLE Medical History (Body System): Musc/Skeletal & Connect Tis-
sue
MHNEOPLA Medical History (Body System): Neoplasms Benign, Malig &
Unspec
MHNERV Medical History (Body System): Nervous System Disorders
MHPSYCH Medical History (Body System): Psychiatric Disorders
MHRENAL Medical History (Body System): Renal & Urinary Disorders
MHRESP Medical History (Body System): Resp, Thoracic & Mediastinal
MHSKIN Medical History (Body System): Skin & Subcutaneous Tissue
MHSOCIAL Medical History (Body System): Social Circumstances
MHSURG Medical History (Body System): Surgical & Medical Procedures
MHVASC Medical History (Body System): Vascular Disorders
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Table 7.2: Previous treatment features.
Feature Name Description
CMINTENT Intented Use of Medication
CMSCAT Subcategory for Medication
CMSSCAT Subsubcategory for Medication





CMDICTV Version of Medical Dictionary reference (MedDRA)
CMDURN Duration of Medication
CMDURU Duration Unit of Medication
VISIT Visit Name (Showing visit schedule)
CMDOSE Dose per Administration
CMDOSFRQ Dosing Frequency per Interval
CMDOSTOT Total Daily Dose
CMDOSTXT Dose Description
CMDOSU Dose Units
CMROUTE Route of Administration
CMPRN Medication PRN Flag
CM AE Treatment for Adverse Event
CMCAT Category for Medication
CMATC1CD Anatomic Class Code
CMATC2CD Therapeutic Class Code
CMATC3CD Pharmacological Class Code
CMATC4CD Chemical Class Code
CMATCCD ATC Code
CMRECNO Medication Drug Record Number
CMSEQ1 Medication Drug Sequence Number 1
CMSEQ2 Medication Drug Sequence Number 2
CMMODIFY Modified Reported Name
CMSTDT PC Medication Start Date period value in days
CMENDT PC Medication End Date period value in days
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Table 7.3: Lab value features.
Feature Name Description
PER REF C Reference day for Lab collection day (LBDT PC)
LBCAT Category for Lab Test
LBTEST Lab Test or Examination Name
LBORRES Result or Finding in Original Units
LBORRESU Unit for the Original Test Result
LBTOXGRC Standard Toxicity Grade Character Value
LBORNRLO Reference Range Lower Limit in Orig Test Result
LBORNRHI Reference Range Upper Limit in Orig Test Result
LBMETHOD Method of Test or Collection
VISIT Visit Name (Showing visit schedule)
LBSTRESC Character Result/Finding in STD format
LBSTNRLO Reference Range Lower Limit- Std Units
LBSTNRHI Reference Range Upper Limit- Std Units
LBTESTCD Lab Test or Examination Short Name
LBSCAT Subcategory for Lab Test
LBSTAT Completion Status of the Lab Test
LBBLFL Baseline Flag for Lab Value
LBTOXGR Standard Toxicity Grade
LBTOXGRN Standard Toxicity Grade Numeric Code
LBNRIND Reference Range Indicator
LBACPT Actual Timepoint Name
LBTM Time of Specimen Collection
LBTX Time of Specimen Collection (Char)
LBDRVFL Flag for Derived value
LBSTRECI Reporting Character Result/Finding
LBSTREIU Reporting Result/Finding Unit
LBSTRENI Num Result/Finding in Std Units Imputed
LBSTRESN Numeric Result/Finding in Standard units
LBSTRESU Standard Units
LBORNRU Original Units for Reference Range
LBSTNRC Reference Range for Char Rslt-Std Units
LBDT PC Date specimen collected period value in days
29
Table 7.4: Lesion measure features.
Feature Name Description
PER REF C Reference day for lesion assessment day (LSDT PC)
VISIT Visit Name (Showing visit schedule)
LSCAT Category for Lesions
LSTEST Lesion Test Name
LSLOC Location of Tumor
LSLOC2 Location of Tumor Grouping
LSORRES Result or Finding in Original Units
LSORRESU Original Units




LSREASND Reason Not Performed
LSSLOC Location of Tumor (subcategory)
LSSTRESC Character Result/Finding in Std Format
LSSTRESN Numeric Result/Finding in Standard Units
LSSTRESU Standard Units
LSTESTCD Short Name of LSTEST
LSCOM Lesion Comment
LSDT PC Assessment Date period value in days
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Table 7.5: Medical history features.
MHTERM Reported Term for the Medical History
MHDECOD Dictionary-Derived Term
MHBODSYS Body System or Organ Class
MHSTDT P Start Event Date period value in days
MHLLT Lowest Level Term
MHHLT High Level Term
MHHLGT High Level Group Term
MHDICTV Dictionary Version
MHENRF End Relative to Reference Period
VISIT Visit Name
VISITNUM Visit Number
MHCAT Category for Medical History
MHPTCD Prefered Term Code
MHSOC1FL Primary System Organ Class (SOC) Flag
MHSOCCD System Organ Class Code
MHHLGTCD High Level Group Term Code
MHHLTCD High Level Term Code
MHLLTCD Lowest Level Term Code
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Table 7.6: Vital sign features.
PER REF C Reference day for vital sign capture day (VSDT PC)
VSTEST Vital Signs Test Name
VSORRES Result or Finding in Original Units
VSORRESU Original Units
VSSTRESC Character Result/Finding in STD format
VSSTRESU Standard Units
VISIT Visit Name (Showing visit schedule)
VSBLFL Baseline Flag
VSACTPT Actual Timepoint Name
VSACTPTN Actual Timepoint Number
VSDRVFL Derived Flag
VSSTRESN Numeric Result/Finding in Standard units
VSTESTCD Vital Signs Test Short Name
VSDT PC Date taken period value in days
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